The U.K. agency that evaluates the cost effectiveness of prescription drugs has recommended the government pay for the controversial Sovaldi hepatitis C treatment, although not for all patients.
The move, which still requires a final endorsement, comes as the medicine causes a ruckus in the U.S. The price tag–$84,000 for a 12-week regimen–has insurers and state Medicaid directors worried that the Gilead Sciences GILD +2.62% medication will become a budget buster and helped to fuel a national debate over the rising cost of prescription drugs.
Read More